Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1214-1221

  Briasoulis, Alexandros ^a   Tousoulis, Dimitris ^a   Papageorgiou, Nikolaos ^a   Kampoli, Anna Maria ^a   Androulakis, Emmanuel ^a   Antoniades, Charalambos ^a   Tsiamis, Eleftherios ^a   Latsios, George ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; CP 471474; DOXYCYCLINE; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE INHIBITOR; PG 116800; PG 166793; PGE 530742; PGE 7113313; PLACEBO; RXP 470; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TETRACYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; LOCALIZED HIGH FREQUENCY STIMULATION; MACROPHAGE; NONHUMAN; PROTEIN TARGETING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY;

EID: 84861130637     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011214     Document Type: Article

References (63)

1. Massova, I.; Kotra, L.P.; Fridman, R.; Mobashery, S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB. J. 1998, 12(12), 1075-1095.
2. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92(8), 827-839.
3. Baker, A.H.; Edwards, D.R.; Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci., 2002, 115(Pt 19), 3719-3727.
4. Williamson, R.A.; Marston, F.A.; Angal, S.; Koklitis, P.; Panico, M.; Morris, H.R.; Carne, A.F.; Smith, B.J.; Harris, T.J.; Freedman, R.B. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J., 1990, 268(2), 267-274.
5. Creemers, E.E.; Cleutjens, J.P.; Smits, J.F.; Daemen, M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res., 2001, 89 (3), 201-210.
6. Lambert, E.; Dasse, E.; Haye, B.; Petitfrere, E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol., 2004, 49(3), 187-198.
7. Clark, I.M.; Swingler, T.E.; Sampieri, C.; Edwards, D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell. Biol. 2008, 40(6-7), 1362-1378.
8. Zhong, Z.D.; Hammani, K.; Bae, W.S.; De Clerck, Y.A. NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2. J. Biol. Chem., 2000, 275(24), 18602-18610.
9. Tanaka, K.; Iwamoto, Y.; Ito, Y.; Ishibashi, T.; Nakabeppu, Y.; Sekiguchi, M.; Sugioka, Y. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer. Res., 1995, 55(13), 2927-2935.
10. Buzzio, O.L.; Lu, Z.; Miller, C.D.; Unterman, T.G.; Kim, J.J. FOXO1A differentially regulates genes of decidualization. Endocrinology., 2006, 147(8), 3870-3876.
11. Clark, I.M.; Rowan, A.D.; Edwards, D.R.; Bech-Hansen, T.; Mann, D.A.; Bahr, M.J.; Cawston, T.E. Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem. J., 1997, 324(Pt 2), 611-617.
12. Hammani, K.; Blakis, A.; Morsette, D.; Bowcock, A.M.; Schmutte, C.; Henriet, P.; DeClerck, Y.A. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J. Biol. Chem., 1996,271(41), 25498-25505.
13. Sun, Y.; Hegamyer, G.; Kim, H.; Sithanandam, K.; Li, H.; Watts, R.; Colburn, N.H. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J. Biol. Chem., 1995, 270(33), 19312-19319.
14. Young, D.A.; Phillips, B.W.; Lundy, C., Nuttall, R.K.; Hogan, A.; Schultz, G.A.; Leco, K.J.; Clark, I.M.; Edwards, D.R. Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem. J., 2002, 364(Pt 1), 89-99.
15. Rouis, M.; Adamy, C.; Duverger, N.; Lesnik, P.; Horellou, P.; Moreau, M.; Emmanuel, F.; Caillaud, J.M.; Laplaud, P.M.; Dachet, C.; Chapman, M.J. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E deficient mice. Circulation., 1999, 100(5), 533-540.
16. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ. Res., 2002, 90(8), 897-903.
17. Bendeck, M.P.; Zempo, N.; Clowes, A.; Galardy, R.E.; Reidy, M.A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res., 1994, 75(3), 539-545.
18. Bendeck, M.P.; Irvin, C.; Reidy, M.A. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res., 1996, 78(1), 38-43.
19. Cherr, G.; Motew, S.; Travis, J.; Fingerle, J.; Fisher, L.; Brandl, M.; Williams, J.K.; Geary, R.L. Metalloproteinase Inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler. Thromb. Vasc. Biol., 2002, 22(1), 161-166.
20. de Smet, B.J.; de Kleijn, D.; Hanemaaijer, R.; Verheijen, J.H.; Robertus, L., van Der Helm, Y.J.; Borst, C.; Post, M.J. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty. Circulation., 2000, 10(25), 2962-2967.
21. Cheng, L.; Mantile, G.; Pauly, R.; Nater, C.; Felici, A.; Monticone, R.; Bilato, C.; Gluzband, Y.A.; Crow, M.T.; Stetler-Stevenson, W.; Capogrossi, M.C. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation., 1998, 98(20), 2195-2201.
22. Dollery, C.M.; Humphries, S.E.; McClelland, A.; Latchman, D.S.; McEwan, J.R. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation., 1999, 99(24), 3199-3205.
23. George, S.J.; Zaltsman, A.B.; Newby, A.C. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc. Res., 1997, 33(2), 447-459.
24. George, S.J.; Baker, A.H.; Angelini, G.D.; Newby, A.C. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene. Therapy., 1998, 5(11), 1552-1560.
25. George, S.J.; Johnson, J.L.; Angelini, G.D.; Newby, A.C.; Baker, A.H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Hum. Gene. Ther., 1998, 9(6), 867-877.
26. George, S.J.; Lloyd, C.T.; Angelini, G.D.; Newby, A.C.; Baker, A.H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation., 2000,101(3), 296-304.
27. Johnson, J.L.; Baker, A.H.; Oka, K.; Chan, L., Newby, A.C.; Jackson, C.L.; George, S.J. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation., 2006, 113(20), 2435-2444.
28. Johnson, J.L.; Fritsche-Danielson, R.; Behrendt, M.; Westin-Eriksson, A.; Wennbo, H.; Herslof, M.; Elebring, M.; George, S.J.; McPheat, W.L.; Jackson, C.L. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc. Res., 2006, 71(3), 586-595.
29. Silence, J.; Lupu, F.; Collen, D.; Lijnen, H.R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol., 2001, 21(9), 1440-1445.
30. Luttun, A.; Lutgens, E.; Manderveld, A.; Maris, K.; Collen, D.; Carmeliet, P.; Moons, L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation., 2004, 109(11), 1408-1414.
31. Johnson, J.L.; George, S.J.; Newby, A.C.; Jackson, C.L. Divergent effects of matrix metalloproteinases-3,-7,-9 and-12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U S A., 2005, 102(43), 15575-15580.
32. Wilson, E.M.; Moainie, S.L.; Baskin, J.M.; Lowry, A.S.; Deschamps, A.M.; Mukherjee, R.; Guy, T.S.; St John-Sutton, M.G.; Gorman, J.H. 3rd; Edmunds, L.H. Jr; Gorman, R.C.; Spinale, F.G. Region-and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation., 2003,107(22), 2857-2863.
33. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L.E.; Schoen, F.J.; Kelly, R.A.; Werb, Z.; Libby, P.; Lee, R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest., 2000, 106 (1), 55-62.
34. Hayashidani, S.; Tsutsui, H.; Ikeuchi, M.; Shiomi, T.; Matsusaka, H.; Kubota, T.; Imanaka-Yoshida, K.; Itoh, T.; Takeshita, A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart. Circ. Physiol., 2003, 285(3), H1229-H1235.
35. Lindsey, M.L.; Gannon, J.; Aikawa, M.; Schoen, F.J.; Rabkin, E.; Lopresti-Morrow, L.; Crawford, J.; Black, S.; Libby, P.; Mitchell, P.G.; Lee, R.T. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation., 2002, 105(6), 753-738.
36. Yarbrough, W.M.; Mukherjee, R.; Escobar, G.P.; Mingoia, J.T.; Sample, J.A.; Hendrick, J.W.; Dowdy, K.B.; McLean, J.E.; Lowry, A.S.; O'Neill, T.P.; Spinale, F.G. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation., 2003, 108(14), 1753-1759.
37. King, M.K.; Coker, M.L.; Goldberg, A.; McElmurray, J.H. 3rd; Gunasinghe, H.R.; Mukherjee, R.; Zile, M.R.; O'Neill, T.P.; Spinale, F.G. Selective matrix metalloproteinase inhibition with developing heart failure. Effects on left ventricular function and structure. Circ. Res., 2003, 92(2), 177-185.
38. Matsumura, S.; Iwanaga, S.; Mochizuki, S.; Okamoto, H.; Ogawa, S.; Okada, Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest., 2005, 115(3), 599-609.
39. Apple, K.A.; Yarbrough, W.M.; Mukherjee, R.; Deschamps, A.M.; Escobar, P.G.; Mingoia, J.T.; Sample, J.A.; Hendrick, J.W.; Dowdy, K.B.; McLean, J.E.; Stroud, R.E.; O'Neill, T.P.; Spinale, F.G. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J. Cardiovasc. Pharmacol., 2006, 47(2), 228-235.
40. Peterson, J.T.; Hallak, H.; Etoh, T.; Spinale, F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation., 2001, 103(18), 2303-2309.
41. Hudson, M.P.; Armstrong, P.W.; Ruzyllo, W.; Brum, J.; Cusmano, L.; Krzeski, P.; Lyon, R.; Quinones, M.; Theroux, P.; Sydlowski, D.; Kim, H.E.; Garcia, M.J.; Jaber, W.A.; Weaver, W.D. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol., 2006, 48(1), 15-20.
42. Johnson, J.L.; Devel, L.; Czarny, B.; George, S.J.; Jackson, C.L.; Rogakos, V.; Beau, F.; Yiotakis, A.; Newby, A.C.; Dive, V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler. Thromb. Vasc. Biol., 2011, 31(3), 528-535.
43. Bench, T.J.; Jeremias, A.; Brown, D.L. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol. Res., 2011, 64(6), 561-6.
44. Meier, C.R.; Derby, L.E.; Jick, S.S.; Vasilakis, C.; Jick, H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA., 1999, 281(5), 427-431.
45. Axisa, B.; Loftus, I.M.; Naylor, A.R.; Goodall, S.; Jones, L.; Bell, P.R.; Thompson, M.M. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke., 2002, 33(12), 2858-2864.
46. Shapira, L.; Soskolne, W.A.; Houri, Y.; Barak, V.; Halabi, A.; Stabholz, A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun., 1996, 3(3), 825-828.
47. Bendeck, M.P.; Conte, M.; Zhang, M.; Nili, N.; Strauss, B.H.; Farwell, S.M. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial lesions. Am. J. Pathol., 2002, 160(3), 1089-1095.
48. Kirkwood, K.L.; Golub, L.M.; Bradford, P.G. Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts. Ann. N.Y. Acad. Sci., 1999, 878, 667-670.
49. Smith, G.N.; Brandt, K.D.; Hasty, K.A. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis. Rheum., 1996, 39(2), 235-244.
50. Manning, M.W., Cassis, L.A., Daughtery, A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol., 2003, 23(3), 483-488.
51. Baxter, B.T.; Pearce, W.H.; Waltke, E.A.; Littooy, F.N.; Hallett, J.W. Jr.; Kent, K.C.; Upchurch, G.R. Jr.; Chaikof, E.L.; Mills, J.L.; Fleckten, B.; Longo, G.M.; Lee, J.K.; Thompson, R.W. Prolonged administration of doxycycline in patients with small asymptomatic aortic aneurysms: report of a prospective (phase II) multicenter study. J. Vasc. Surg., 2002, 36(1), 1-12.
52. Mosorin, M.; Juvonen, J.; Biancari, F.; Satta, J.; Surcel, H.M.; Leinonen, M.; Saikku, P.; Juvonen, T. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebocontrolled pilot study. J. Vasc. Surg., 2001, 34(4), 606-610.
53. Danesh, J.; Whincup, P.; Walker, M.; Lennon, L.; Thomson, A.; Appleby, P.; Wong, Y.; Bernardes-Silva, M.; Ward, M. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ, 2000, 321(7255), 208-212.
54. Brown, D.L.; Desai, K.K.; Vakili, B.A.; Nouneh, C.; Lee, H.M.; Golub, L.M. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol., 2004, 24(4), 733-738.
55. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M. Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.; 2008, 359(21), 2195-2207.
56. Axisa, B.; Loftus, I.M.; Naylor, A.R.; Goodall, S.; Jones, L.; Bell, P.R.; Thompson, M.M. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke., 2002, 33(12), 2858-2864.
57. Son, J.W.; Koh, K.K.; Ahn, J.Y.; Jin, D.K.; Park, G.S.; Kim, D.S.; Shin, E.K. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int. J. Cardiol., 2003, 88(1), 77-82.
58. Pollanen, P.J.; Lehtimaki, T.; Ilveskoski, E.; Mikkelsson, J.; Kajander, O.A.; Laippala, P.; Perola, M.; Goebeler, S.; Penttilä, A.; Mattila, K.M.; Syrjäkoski, K.; Koivula, T.; Nikkari, S.T.; Karhunen, P.J. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase-3: the Helsinki Sudden Death Study. Atherosclerosis., 2002, 164(2), 329-335.
59. Bellosta, S.; Via, D.; Canavesi, M.; Pfister, P.; Fumagalli, R.; Paoletti, R.; Bernini, F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 1998, 18(11), 1671-1678.
60. Koh, K.K.; Ahn, J.Y.; Jin, D.K.; Han, S.H.; Kim, H.S.; Choi, I.S.; Ahn, T.H.; Shin, E.K; Jeong, E.M. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int. J. Cardiol., 2004, 97(2), 239-244.
61. Luan, Z.; Chase, A.J.; Newby, A.C. Statins inhibit secretion of metalloproteinases-1-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol., 2003, 23(5), 769-775.
62. Lopez-Cuenca, A.; Marin, F.; Roldan, V.; Climent, V.E.; Valdés, M.; Lip, G.Y. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease. Int. J. Cardiol.; 2010, 139(1), 95-97.
63. Mukherjee, R.; Rivers, W.T.; Ruddy, J.M.; Matthews, R.G.; Koval, C.N.; Plyler, R.A.; Chang, E.I.; Patel, R.K.; Kern, C.B.; Stroud, R.E., Spinale, F.G. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation., 2010, 122(1), 20-32.